Immunome, Inc. IMNM
Set alert
20.33 USD +0.73 +3.75%
As of Nov 3, 2:01 PM ET
19.78 Day range 20.43
14.64 52-week range 30.06
- YTD
- -5.38%
- 1 year
- +19.56%
- Open
- 19.81
- Prev close
- 19.59
- Mkt cap
- 2.40B
- Vol
- 552.22K
- Avg vol
- 1.30M
- EPS
- -2.52
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 19.78
- High
- 20.43
- Forward P/E
- -7.97
- Beta
- 2.66
- Short ratio
- 10.98
- Inst. own
- 103.76%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 22.44
- 200-d avg
- 22.49
- 1y target
- 35.33
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 35.33 +73.8% upside
Now 20.33
- Target (low)
- 24.00
- Target (mean)
- 35.33
- Target (high)
- 40.00
Ratings (0m) 17 16 buy · 1 hold · 0 sell
- Strong buy3
- Buy13
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 17
- 1 month ago 16
- 2 months ago 14
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.5976 | -0.71 – -0.41 | -0.65 | +8.1% | 133.33K | 0.0% | 15 |
| Next quarter | -0.6322 | -0.77 – -0.523 | -0.76 | +16.8% | 133.33K | 0.0% | 15 |
| Current year | -2.33 | -2.56 – -2.02 | -2.43 | +4.2% | 266.67K | -96.2% | 14 |
| Next year | -2.46 | -3.13 – -1.85 | -2.33 | -5.6% | 50.41M | +18804.0% | 13 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 27, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Oct 16, 2026 | William Blair | Initiated | — | Outperform |
| Oct 1, 2026 | Stifel | Initiated | — | Hold |
| Sep 21, 2026 | Alliance Global Partners | Initiated | — | Buy |
| Sep 10, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 12, 2026 | Truist Securities | Maintained | Buy | Buy |
| Aug 12, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Jul 21, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Jun 12, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| May 28, 2026 | Truist Securities | Maintained | Buy | Buy |
| May 28, 2026 | Barclays | Initiated | — | Overweight |
| May 15, 2026 | Leerink Partners | Maintained | Outperform | Outperform |
| May 13, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 4, 2026 | Craig-Hallum | Maintained | Buy | Buy |
| Mar 4, 2026 | Stephens & Co. | Maintained | Overweight | Overweight |
| Feb 12, 2026 | HC Wainwright & Co. | Initiated | — | Buy |
| Jan 15, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Dec 16, 2025 | Lake Street | Maintained | Buy | Buy |
| Dec 16, 2025 | Evercore ISI Group | Maintained | Outperform | Outperform |
| Dec 16, 2025 | Guggenheim | Maintained | Buy | Buy |
| Dec 1, 2025 | Truist Securities | Initiated | — | Buy |
| Nov 17, 2025 | Stephens & Co. | Maintained | Overweight | Overweight |
| Sep 22, 2025 | Goldman Sachs | Initiated | — | Buy |
| Sep 5, 2025 | Craig-Hallum | Initiated | — | Buy |
| Aug 25, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Aug 22, 2025 | Evercore ISI Group | Initiated | — | Outperform |
| Aug 7, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Apr 2, 2025 | Lake Street | Initiated | — | Buy |
| Mar 20, 2025 | Wedbush | Reiterated | Outperform | Outperform |
| Mar 20, 2025 | Stephens & Co. | Reiterated | Overweight | Overweight |